Aptevo Therapeutics Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors

Reuters

06/20

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia $(AML.AU)$, and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1041349) on June 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544212718"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544212718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544212718?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544212718","market":"nz","top_or_hot":-1,"title":"Aptevo Therapeutics Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a>, a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a>, and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1041349) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a>, a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a>, and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1041349) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APVO","symbol_name":"Aptevo Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL5PQvBJ:1","article_id":"2544212718","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544212718","pubTimestamp":1750424120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia , and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.Disclaimer: This news brief was created by Public Technologies  using gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APVO":"Aptevo Therapeutics Inc.","BK4139":"生物科技","BK4583":"猴痘概念","EBS":"Emergent Biosolutions"},"translate_title":"Aptevo Therapeutics推出针对实体瘤的新APVO455候选药物扩大CD3产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9,"EBS":0.9},"content_text":"Aptevo Therapeutics Expands CD3 Portfolio with New APVO455 Candidate Targeting Solid Tumors\n    \n\nAptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia $(AML.AU)$, and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1041349) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}